Donald Thornton
Overview
Explore the profile of Donald Thornton including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
502
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
A Phase 1 Study of LY2874455, an Oral Selective pan-FGFR Inhibitor, in Patients with Advanced Cancer
Michael M, Bang Y, Park Y, Kang Y, Kim T, Hamid O, et al.
Target Oncol
. 2017 Jun;
12(4):463-474.
PMID: 28589492
Background: We report here a phase 1 study of LY2874455, a potent oral selective pan-fibroblast growth factor receptor (FGFR) inhibitor. Objective: The primary objective was to determine the recommended phase...
2.
Galsky M, Vogelzang N, Conkling P, Raddad E, Polzer J, Roberson S, et al.
Clin Cancer Res
. 2014 Apr;
20(13):3581-8.
PMID: 24727324
Purpose: Overexpression of C-X-C motif receptor 4 (CXCR4) is implicated in tumor progression. LY2510924 is a peptide antagonist, which blocks stromal cell-derived factor-1 (SDF1) from CXCR4 binding. Experimental Design: This...
3.
Nwankwo N, Zhang Z, Wang T, Collins C, Resta L, Ermisch S, et al.
Invest New Drugs
. 2012 Jul;
31(3):653-60.
PMID: 22766773
Purpose: Given distinct mechanism of actions of enzastaurin and bevacizumab, preclinical studies suggest enhanced antitumor activity in combination. This phase I study assessed the combination's safety and efficacy. Patients And...
4.
Kreisl T, Kotliarova S, Butman J, Albert P, Kim L, Musib L, et al.
Neuro Oncol
. 2010 Feb;
12(2):181-9.
PMID: 20150385
Enzastaurin, a potent inhibitor of protein kinase C-beta, inhibits angiogenesis and has direct cytotoxic activity against glioma cells in preclinical studies. Patients with recurrent high-grade gliomas were stratified by histology...
5.
Pollok K, Lahn M, Enas N, McNulty A, Graff J, Cai S, et al.
J Oncol
. 2009 Jun;
2009:596560.
PMID: 19503801
Background. The use of 2-[(18)F]fluoro-2-deoxy-D-glucose ([(18)F]FDG) may help to establish the antitumor activity of enzastaurin, a novel protein kinase C-beta II (PKC-betaII) inhibitor, in mouse xenografts. Methods. The hematologic cell...
6.
Kreisl T, Kim L, Moore K, Duic P, Kotliarova S, Walling J, et al.
Clin Cancer Res
. 2009 May;
15(10):3617-23.
PMID: 19417015
Purpose: Enzastaurin is a selective inhibitor of protein kinase C beta. Prior phase I studies did not show increased drug exposures with escalating once daily administration. Limits from gastrointestinal absorption...
7.
Camidge D, Eckhardt S, Gore L, OBryant C, Leong S, Basche M, et al.
Anticancer Drugs
. 2007 Nov;
19(1):77-84.
PMID: 18043132
Enzastaurin, an oral inhibitor of protein kinase Cbeta, affects signal transduction associated with angiogenesis, proliferation, and survival. Capecitabine is converted to 5-fluoruracil by thymidine phosphorylase, a putative angiogenic factor. The...
8.
Robertson M, Kahl B, Vose J, de Vos S, Laughlin M, Flynn P, et al.
J Clin Oncol
. 2007 Mar;
25(13):1741-6.
PMID: 17389337
Purpose: Protein kinase C beta (PKCbeta) was identified by gene-expression profiling, preclinical evaluation, and independent immunohistochemical analysis as a rational therapeutic target in diffuse large B-cell lymphoma (DLBCL). We conducted...
9.
Li S, Phong M, Lahn M, Brail L, Sutton S, Lin B, et al.
Biol Direct
. 2007 Feb;
2:8.
PMID: 17313671
Background: Both mechanistic features and recent correlative findings suggest a potential role for protein kinase C-beta (PKC-beta) in tumor pathogenesis, particularly in B-cell malignancies. To evaluate the role of this...
10.
Green L, Marder P, Ray C, Cook C, Jaken S, Musib L, et al.
Clin Cancer Res
. 2006 Jun;
12(11 Pt 1):3408-15.
PMID: 16740765
Purpose: To evaluate the effects of the novel protein kinase C (PKC) inhibitor enzastaurin on intracellular phosphoprotein signaling using flow cytometry and to use this approach to measure enzastaurin effects...